Author:
MMK Mbula,HNT Situakibanza,GL Mananga,B Longo Mbenza,JRR Makulo,MM Longokolo,MN Mandina,NN Mayasi,MM Mbula,B Bepouka,GL Mvumbi,EN Amaela,DN Tshilumba,O Odio,BM Ekila,A Nkodila,BT Buasa
Abstract
Background and aim: Metabolic abnormalities are common in HIV/AIDS. Increasingly, lipid ratios are used as screening tools for dyslipidaemia in these medical conditions. The aim of this study was to assess the ability of 4 lipid ratios to predict cardiovascular risks. Methods: This is a cross-sectional and analytical study included 105 HIV+ patients followed in Kinshasa University Teaching Hospital (KUTH). Four indices [Atherogenic Index of Plasma (AIP), Castelli Risk Index (CRI) I and II, Atherogenic coefficient (AC)] were compared. Statistical analyzis consisted of measuring frequencies and means, Student’s t-tests, ANOVA and Ficher’s exact test, and the calculation of the Kappa value. Results: Lipid ratios predicted respectively the risk in 62% (AIP), 28.6% (CRI-I) and 23.8% (CRI-II). CRI-I and II were elevated, especially in women. The AIP appeared to be a better predictor than CRI-I and II to assess dyslipidaemia in general and the high-risk frequency. The cholesterol detected risk in 66.7% (Low HDL-C), 50% (High LDL-C), 38.9% (High TC and/or TG). The atherogenic risk was higher with age, advanced WHO stage, HIV-TB, HBV-HCV co-infections, smoking and alcohol intake. Haemoglobin (Hb) and CD4 counts were low when the risk was high. Age ≥ 50 years, stage 4 (WHO), CD4s+ ≤ 200 cells/µL were independent factors associated with atherogenic risk. Conclusion: Lipid ratios can be used as reliable tools for assessing cardiovascular risk of naïve HIV-infected patients who received HAART.
Publisher
Heighten Science Publications Corporation
Reference32 articles.
1. 1. Deeks S, Lewin SR, Havlir DV. The end of AIDS infection as a chronic disease. The Lancet. 2013; 382: 1525-1533. PubMed: https://pubmed.ncbi.nlm.nih.gov/24152939/
2. 2. Serrano-Villar S, Gutiérrez F, Miralles C, Berenguer J, Rivero A, et al. Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions. Open Forum Infect Dis. 2016; 3: 097. PubMed: https://pubmed.ncbi.nlm.nih.gov/27419169/
3. 3. Pirillo A, Catapano AL, Norata GD. HDL in Infectious Diseases and Sepsis. In: von Eckardstein A., Kardassis D. (eds) High Density Lipoproteins. Handbook of Experimental Pharmacology. 2015; 224: 483-508. PubMed: https://pubmed.ncbi.nlm.nih.gov/25522999/
4. 4. Feingold KR, Grunfeld C. The Effect of Inflammation and Infection on Lipids and Lipoproteins. [Updated 2019 Jan 8]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. PubMed: https://www.ncbi.nlm.nih.gov/books/NBK326741/
5. 5. Reis RP. Cardiovascular Risk in HIV-infected patient. Rev Port Cardiol. 2019; 38: 471- 472. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964878/